Trial Profile
An extension study for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development (Study 208).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2015
Price :
$35
*
At a glance
- Drugs Retigabine (Primary)
- Indications Generalised epilepsy; Partial epilepsies
- Focus Adverse reactions; Therapeutic Use
- 20 Dec 2015 New trial record